A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

Hot Flashes Clinical Trial

Official title:
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women

Status Completed

Clinical Trial Summary

Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life. The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people. In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo looks like a treatment but does not have any medicine in it. To compare these study treatments, the doctors will ask the participants to record information about the participants' hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe the hot flashes are. The researchers will look at the results from before treatment, after 4 weeks, and after 12 weeks of treatment. The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants who take elinzanetant will take it for 26 weeks. The participants who take the placebo will take it for 12 weeks and then take elinzanetant for the next 14 weeks. During the study, the participants will visit the site approximately 9 times and perform 1 visit by phone. Each participant will be in the study for approximately 36 weeks. The treatment duration will be 26 weeks. During the study, the participants will: - record information about the participants' hot flashes in an electronic diary - answer questions about the participants' symptoms The doctors will: - check the participants' health - take blood samples - ask the participants questions about what medicines the participants are taking and if the participants are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if doctors do not think the adverse events might be related to the study treatments.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hot Flashes
Vasomotor Symptoms Associated With Menopause

Clinical Trial Details

NCT number	NCT05099159
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 3
Start date	October 29, 2021
Completion date	October 10, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04587154` - Womens Study to Alleviate Vasomotor Symptoms	N/A
Terminated	`NCT03642119` - Validation of an Objective Instrument to Measure Hot Flashes During Menopause
Completed	`NCT05061563` - A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults	Phase 1
Completed	`NCT05419908` - Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes	Phase 2
Completed	`NCT01281332` - Mechanical Device for the Relief of Hot Flashes	Phase 2
Completed	`NCT01439945` - Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer	Phase 2
Completed	`NCT00755417` - Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women	Phase 3
Completed	`NCT01293695` - Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial	N/A
Completed	`NCT00599456` - Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.	N/A
Completed	`NCT00256685` - Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause	Phase 3
Completed	`NCT00391417` - Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms	Phase 3
Terminated	`NCT00244894` - Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer	N/A
Completed	`NCT00010712` - Effects of Black Cohosh on Menopausal Hot Flashes	Phase 2
Active, not recruiting	`NCT03580499` - Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy	N/A
Recruiting	`NCT06030388` - Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women	N/A
Recruiting	`NCT04418115` - Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?	N/A
Recruiting	`NCT04861701` - Effect and Predictors for Hot Flush in Women Undergoing Static Stretching Exercise	N/A
Active, not recruiting	`NCT05086705` - EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer	N/A
Completed	`NCT01140646` - Evaluation of SAMe for Hot Flashes	Phase 2
Completed	`NCT00956813` - Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy	Phase 3